Company

Genentech

South San Francisco biotechnology pioneer, founded 1976 and a wholly owned member of the Roche Group since 2009; makes obinutuzumab (Gazyva), now approved for lupus nephritis, certain blood cancers and childhood-onset nephrotic syndrome.

gene.com

1 story

Regulatory News has published 1 story about Genentech on 28 September 2026, sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 28 September 2026.

This page is generated from Regulatory News’ editorial coverage of Genentech. It is not an advertisement.

Products in our coverage

Gazyvaobinutuzumab

Our coverage

1 story, newest first.

A physician in a white coat and scrubs writes in a notebook beside a stethoscope and a tablet

For Physicians FDA Approves First Drug for Relapsing Nephrotic Syndrome Sep 28, 20267 min read Read the story

All companies